MedPath

Paroxetine

Generic Name
Paroxetine
Brand Names
Paxil, Pexeva
Drug Type
Small Molecule
Chemical Formula
C19H20FNO3
CAS Number
61869-08-7
Unique Ingredient Identifier
41VRH5220H
Background

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.

Indication

Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).

Associated Conditions
Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance

Not Applicable
Terminated
Conditions
Sleep Disorders
Stress Disorders, Post-Traumatic
Interventions
First Posted Date
2005-09-20
Last Posted Date
2018-07-10
Lead Sponsor
Seattle Institute for Biomedical and Clinical Research
Target Recruit Count
59
Registration Number
NCT00202449
Locations
🇺🇸

Madigan Army Medical Center, Fort Lewis, Washington, United States

🇺🇸

Walter Reed Army Medical Center, Washington, District of Columbia, United States

Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin

Phase 3
Completed
Conditions
Chronic Hepatitis C
First Posted Date
2005-09-20
Last Posted Date
2009-05-13
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
144
Registration Number
NCT00196664
Locations
🇫🇷

Service d'Hépato-gastroentérologie CHU de Nancy, Vandoeuvre, France

Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder

Phase 2
Completed
Conditions
Social Phobia
First Posted Date
2005-09-19
Last Posted Date
2007-02-13
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
185
Registration Number
NCT00191022
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, West Allis, Wisconsin, United States

Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder

Phase 3
Completed
Conditions
Panic Disorders
First Posted Date
2005-09-19
Last Posted Date
2010-04-02
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Target Recruit Count
70
Registration Number
NCT00195598

Sleep Deprivation Plus Paroxetine for Treating Major Depression in Elderly Individuals

Phase 4
Completed
Conditions
Depression
First Posted Date
2005-09-15
Last Posted Date
2013-08-02
Lead Sponsor
University of Pittsburgh
Target Recruit Count
158
Registration Number
NCT00178035
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Paroxetine and Interpersonal Psychotherapy for Maintaining Health and Well-being in Elderly Individuals With Depression

Phase 4
Completed
Conditions
Unipolar Depression
First Posted Date
2005-09-15
Last Posted Date
2013-08-02
Lead Sponsor
University of Pittsburgh
Target Recruit Count
225
Registration Number
NCT00178100
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

Phase 4
Completed
Conditions
Bipolar Disorder
First Posted Date
2005-09-15
Last Posted Date
2005-09-15
Lead Sponsor
University of Pittsburgh
Target Recruit Count
60
Registration Number
NCT00177567
Locations
🇺🇸

University of Pittsubrgh Medical Center, Pittsburgh, Pennsylvania, United States

🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Paroxetine in the Treatment of Chronic Primary Insomnia

Phase 4
Completed
Conditions
Primary Insomnia
Depression
First Posted Date
2005-09-15
Last Posted Date
2005-09-15
Lead Sponsor
University of Pittsburgh
Target Recruit Count
66
Registration Number
NCT00178048
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

🇺🇸

University of Pittsubrgh Medical Center, Pittsburgh, Pennsylvania, United States

Comparing Paroxetine and Duloxetine on Cardiovascular Measures

Phase 2
Completed
Conditions
Depressive Symptoms
First Posted Date
2005-08-29
Last Posted Date
2014-07-21
Lead Sponsor
Duke University
Target Recruit Count
40
Registration Number
NCT00136383
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Study Of Generalized Anxiety Disorder

Phase 2
Completed
Conditions
Anxiety Disorder
Anxiety Disorders
Interventions
Drug: Placebo
First Posted Date
2005-08-26
Last Posted Date
2011-01-31
Lead Sponsor
GlaxoSmithKline
Registration Number
NCT00135525
© Copyright 2025. All Rights Reserved by MedPath